In past two-weeks, the stock of pharmaceutical company tanked 40% from its 52-week high of Rs 442 touched on December 8.
Till 11:52 a.m. a combined 417,700 equity shares changed hands and there were pending sell orders for 142,975 shares on the BSE and NSE.
According to disclosure filed by the company, the promoters had sold nearly two lakh shares worth of Rs 6 crore through open market during last week.
Shree Rasbihari Trading & Investment Pvt Ltd and Chandrakanta Murlidhar Dhoot had disposed 173,896 shares amounting of Rs 5.71 crore of Mangalam Drugs between December 16 and 17, the BSE data shows.
On November 16, 2015, the company’s board had allotted 1.2 million equity shares on conversion of 1.2 million share warrants of Rs 10 each at a premium of Rs 55 per share out of the total 2.65 million warrants allotted to promoter group on preferential basis.
Meanwhile, before stock starts downfall, the market value of the company surged 22 times or 2,110% from Rs 20.05 to Rs 442.
Ipca Laboratories, which held 10.58% stake in Mangalam Drugs at the beginning of the current calendar year, had sold its entire holding in the company during first half of 2015, the shareholding pattern data shows. Since June 2015, the stock rallied 780% from Rs 58.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)